AI assistant
NovoCure Ltd — Director's Dealing 2022
Mar 8, 2022
31949_dirs_2022-03-07_28a26ef0-88a7-43ea-89d4-abd761b4fca7.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: NovoCure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2022-03-03
Reporting Person: Longsworth Todd Christopher (General Counsel)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-03-03 | Ordinary Shares | S | 1094 | $74.498 | Disposed | 66774 | Direct |
| 2022-03-04 | Ordinary Shares | S | 1973 | $70.407 | Disposed | 64801 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-03-03 | Options to Buy Ordinary Shares | $80.59 | A | 6106 | Acquired | 2032-02-29 | Ordinary Shares (6106.0) | Direct |
Footnotes
F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F2: Options to buy 6,106 ordinary shares will vest and become exercisable in equal installments on each of March 1, 2023 and 2024, subject to the reporting person's continued employment through such dates.